search
Back to results

The MARVIN Chatbots to Provide Information for Different Health Conditions

Primary Purpose

HIV Infections, Breast Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MARVIN
MARVIN-Pharma
MARVINA
Sponsored by
McGill University Health Centre/Research Institute of the McGill University Health Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for HIV Infections focused on measuring Chatbot, Intelligent Conversational Agent, Co-Construction, Adherence, Antiretroviral Therapy, mHealth, Implementation Science, Care, Breast Cancer, HIV, Self-Management

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria for all objectives: being 18 years or older; being fluent in English and/or French; being able to understand the requirements of study participation and provide informed consent during the duration of the study; having access to a smartphone, tablet, or computer at home/at workplace; having access to an internet connection at home or data plan on their device. Inclusion Criteria Specific to objectives 2 and 3: accept to use a Facebook Messenger-based Chatbot; accept to use or create a personal Facebook account; accept Facebook's privacy and data security policies. Exclusion Criteria: not meeting the inclusion criteria any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Other

    Other

    Other

    Arm Label

    MARVIN: a Chatbot for HIV patients

    MARVIN: a Chatbot for Community Pharmacists

    MARVINA: a Chatbot for Breast Cancer Patients

    Arm Description

    Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

    Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

    Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements

    Outcomes

    Primary Outcome Measures

    Usability Metric for User eXperience (UMUX-Lite)
    The UMUX-Lite is a 2-item questionnaire, answered on a 7-point Likert scale (1 = strongly disagree to 5 = strongly agree), that was deemed appropriate for evaluating medical technology. The items ask whether the chatbot meets the user's needs and the user's perceived ease of use. Scores range from 0 to 100, with more than 68 being considered high usability according to the literature.
    Acceptability E-Scale (AES)
    The AES contains 6 items rated with different 5-point Likert scales (e.g., 1=very difficult to 5=very easy). It is a validated measure of acceptability and usability of computer-based interventions for health populations. Scores range from 0 to 30, and according to the literature, scores above 24 are considered high acceptability.
    Change in Acceptability E-Scale (AES) over 12 months
    The AES contains 6 items rated with different 5-point Likert scales (e.g., 1=very difficult to 5=very easy). It is a validated measure of acceptability and usability of computer-based interventions for health populations. Scores range from 0 to 30, and according to the literature, scores above 24 are considered high acceptability.
    Change in Intervention Appropriateness Measure (IAM) over 12 months
    Appropriateness relates to the relevance or compatibility of the innovation to address a particular issue or problem. The compatibility of an information technology innovation is the extent of which it is considered consistent with users' values, needs, and past experiences. The Compatibility Subscale is a validated tool that contains three items and evaluates on 7-points Likert scales (1 = extremely disagree to 7 = extremely agree) how an IT innovation "fits" with the user's work style. A modified version could be used by healthcare professionals, such as pharmacists.
    Change in Compatibility Subscale over 12 months
    Appropriateness relates to the relevance or compatibility of the innovation to address a particular issue or problem. The compatibility of an information technology innovation is the extent of which it is considered consistent with users' values, needs, and past experiences. A validated tool that could be used by patients is the Intervention Appropriateness Measure (IAM). It also contains 4 items scored on a five-point Likert scale (1=strongly disagree to 5=strongly agree) of agreement evaluating how the innovation is suitable for users.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 14, 2023
    Last Updated
    March 27, 2023
    Sponsor
    McGill University Health Centre/Research Institute of the McGill University Health Centre
    Collaborators
    Centre hospitalier de l'Université de Montréal (CHUM)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05789901
    Brief Title
    The MARVIN Chatbots to Provide Information for Different Health Conditions
    Official Title
    A Master Research Protocol to Adapt and Evaluate an Artificial Intelligence Based Conversational Agent to Provide Information for Different Health Conditions: the MARVIN Chatbots
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    May 1, 2023 (Anticipated)
    Primary Completion Date
    December 31, 2033 (Anticipated)
    Study Completion Date
    December 31, 2034 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    McGill University Health Centre/Research Institute of the McGill University Health Centre
    Collaborators
    Centre hospitalier de l'Université de Montréal (CHUM)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
    Detailed Description
    From 2020, the Principal Investigator's team has developed an innovative chatbot named Minimal AntiretRoViral INterference (MARVIN), for people with HIV. The primary objectives with this master protocol are to: 1) develop or adapt the MARVIN chatbots for different healthcare contexts through co-construction; 2) evaluate the global usability of individual chatbots in their respective use scenarios with a small sample of research participants; 3) evaluate the implementation and user outcomes (e.g., fidelity, appropriateness) of individual chatbots in their respective use scenarios with a larger sample of research participants. This includes also documentation of factors that inhibit or enhance the utilization of the chatbots and outcomes; and 4) establish and evaluate, through the previous objectives, different partnerships with research participants and research team members to co-construct chatbots that will respond to their needs and encourage continued use of the tool.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HIV Infections, Breast Cancer
    Keywords
    Chatbot, Intelligent Conversational Agent, Co-Construction, Adherence, Antiretroviral Therapy, mHealth, Implementation Science, Care, Breast Cancer, HIV, Self-Management

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    The investigators adopt a platform trial design, which is defined as "a study designed to evaluate multiple interventions in the context of a single disease in a perpetual manner, with therapies allowed to enter or leave the platform on the basis of a decision algorithm.". Platform trials can also integrate elements of basket trial design, which aims to study a single intervention for different diseases. In the current case, with different healthcare settings and diseases or conditions under study, the investigators would have a mix of platform trial and basket trial designs for an adaptative platform trial design. Such will allow flexibility in handling multiple interventions adapted to different populations while retaining platform trial characteristics, such as early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms. Meanwhile, there is no initial fixed duration or sample size for each arm.
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    400 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    MARVIN: a Chatbot for HIV patients
    Arm Type
    Other
    Arm Description
    Co-construction of the chatbot, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
    Arm Title
    MARVIN: a Chatbot for Community Pharmacists
    Arm Type
    Other
    Arm Description
    Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
    Arm Title
    MARVINA: a Chatbot for Breast Cancer Patients
    Arm Type
    Other
    Arm Description
    Co-construction of the chatbots, Usability study, Implementation, Evaluation of outcomes and Continuous improvements
    Intervention Type
    Other
    Intervention Name(s)
    MARVIN
    Intervention Description
    Chatbot on Meta (Facebook) Messenger for HIV Patients
    Intervention Type
    Other
    Intervention Name(s)
    MARVIN-Pharma
    Intervention Description
    Chatbot on Meta (Facebook) Messenger for community pharmacists
    Intervention Type
    Other
    Intervention Name(s)
    MARVINA
    Intervention Description
    Chatbot on Meta (Facebook) Messenger for breast cancer patients
    Primary Outcome Measure Information:
    Title
    Usability Metric for User eXperience (UMUX-Lite)
    Description
    The UMUX-Lite is a 2-item questionnaire, answered on a 7-point Likert scale (1 = strongly disagree to 5 = strongly agree), that was deemed appropriate for evaluating medical technology. The items ask whether the chatbot meets the user's needs and the user's perceived ease of use. Scores range from 0 to 100, with more than 68 being considered high usability according to the literature.
    Time Frame
    Immediately, after 1-month of testing - objective 2
    Title
    Acceptability E-Scale (AES)
    Description
    The AES contains 6 items rated with different 5-point Likert scales (e.g., 1=very difficult to 5=very easy). It is a validated measure of acceptability and usability of computer-based interventions for health populations. Scores range from 0 to 30, and according to the literature, scores above 24 are considered high acceptability.
    Time Frame
    Immediately after 1-month of testing - objective 2
    Title
    Change in Acceptability E-Scale (AES) over 12 months
    Description
    The AES contains 6 items rated with different 5-point Likert scales (e.g., 1=very difficult to 5=very easy). It is a validated measure of acceptability and usability of computer-based interventions for health populations. Scores range from 0 to 30, and according to the literature, scores above 24 are considered high acceptability.
    Time Frame
    Once every 3 months within 12 months
    Title
    Change in Intervention Appropriateness Measure (IAM) over 12 months
    Description
    Appropriateness relates to the relevance or compatibility of the innovation to address a particular issue or problem. The compatibility of an information technology innovation is the extent of which it is considered consistent with users' values, needs, and past experiences. The Compatibility Subscale is a validated tool that contains three items and evaluates on 7-points Likert scales (1 = extremely disagree to 7 = extremely agree) how an IT innovation "fits" with the user's work style. A modified version could be used by healthcare professionals, such as pharmacists.
    Time Frame
    Once every 3 months within 12 months
    Title
    Change in Compatibility Subscale over 12 months
    Description
    Appropriateness relates to the relevance or compatibility of the innovation to address a particular issue or problem. The compatibility of an information technology innovation is the extent of which it is considered consistent with users' values, needs, and past experiences. A validated tool that could be used by patients is the Intervention Appropriateness Measure (IAM). It also contains 4 items scored on a five-point Likert scale (1=strongly disagree to 5=strongly agree) of agreement evaluating how the innovation is suitable for users.
    Time Frame
    Once every 3 months within 12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria for all objectives: being 18 years or older; being fluent in English and/or French; being able to understand the requirements of study participation and provide informed consent during the duration of the study; having access to a smartphone, tablet, or computer at home/at workplace; having access to an internet connection at home or data plan on their device. Inclusion Criteria Specific to objectives 2 and 3: accept to use a Facebook Messenger-based Chatbot; accept to use or create a personal Facebook account; accept Facebook's privacy and data security policies. Exclusion Criteria: not meeting the inclusion criteria any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Bertrand Lebouché, MD
    Phone
    514-843-2090
    Email
    bertrand.lebouche@mcgill.ca
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Bertrand Lebouché, MD
    Organizational Affiliation
    McGill University Health Centre/Research Institute of the McGill University Health Centre
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    The MARVIN Chatbots to Provide Information for Different Health Conditions

    We'll reach out to this number within 24 hrs